PUBLISHER: The Business Research Company | PRODUCT CODE: 1751031
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751031
Juvenile idiopathic arthritis (JIA) diagnosis refers to the medical procedures and tests used to detect JIA, a chronic autoimmune disorder in children that leads to persistent joint inflammation, pain, and stiffness, which can result in long-term joint damage and mobility challenges. It occurs when the immune system mistakenly attacks the body's own joint tissues due to a combination of genetic and environmental factors, causing inflammation that, if left untreated, can lead to growth problems, vision issues, and a diminished quality of life.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary methods for diagnosing juvenile idiopathic arthritis include serological tests, imaging tests, and genetic tests. Serological tests analyze blood to detect specific markers that suggest inflammation or autoimmune activity related to JIA. Key diagnostic technologies include molecular diagnostics, immunoassays, and flow cytometry. Diagnostic services, consultation services, and laboratory services are provided in settings such as hospital laboratories, diagnostic centers, and research institutions.
The juvenile idiopathic arthritis diagnostic market research report is one of a series of new reports from The Business Research Company that provides juvenile idiopathic arthritis diagnostic market statistics, including the juvenile idiopathic arthritis diagnostic industry's global market size, regional shares, competitors with a juvenile idiopathic arthritis diagnostic market share, detailed juvenile idiopathic arthritis diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the juvenile idiopathic arthritis diagnostic industry. This juvenile idiopathic arthritis diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The juvenile idiopathic arthritis diagnostic market size has grown strongly in recent years. It will grow from$4.75 billion in 2024 to $5.04 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to the rising prevalence of juvenile idiopathic arthritis, increased awareness of pediatric autoimmune disorders, early detection initiatives, greater healthcare investments, and a heightened focus on pediatric care.
The juvenile idiopathic arthritis diagnostic market size is expected to see strong growth in the next few years. It will grow to$6.32 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth during the forecast period can be attributed to growing collaborations between research institutions, rising demand for early and accurate diagnostic solutions, increasing prevalence of autoimmune and inflammatory disorders, initiatives by government and healthcare organizations, and the rise of telemedicine and digital health platforms. Key trends in the forecast period include technological advancements, improvements in diagnostic technologies, personalized treatment approaches, and innovations in diagnostic tools.
The rising prevalence of autoimmune disorders is expected to significantly drive the growth of the juvenile idiopathic arthritis (JIA) diagnostic market in the coming years. Autoimmune disorders are conditions in which the immune system erroneously attacks the body's healthy cells, causing inflammation, tissue damage, and chronic health complications. The increasing incidence of autoimmune diseases is linked to a combination of environmental triggers, genetic factors, and lifestyle changes. In the case of juvenile idiopathic arthritis, these disorders cause the immune system to target the synovial tissue in joints, leading to inflammation and potential joint damage. For instance, a report from Versorgungsatlas.de, a Germany-based interactive online platform, indicated that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, representing a prevalence rate of 8.61%. Therefore, the growing incidence of autoimmune disorders is driving the demand for juvenile idiopathic arthritis diagnostics.
Leading companies in the juvenile idiopathic arthritis diagnostic market are increasingly forming strategic partnerships to expand their product offerings, enhance research capabilities, and strengthen their global market presence. These partnerships focus on advancing early detection and more accurate diagnosis. For example, in November 2024, Augurex Life Sciences Corp., a biotechnology company based in Canada, entered into a partnership with Quest Diagnostics, a US-based diagnostic services company, to improve the diagnosis and management of rheumatoid arthritis (RA) through the use of the 14-3-3η (eta) biomarker. As part of the collaboration, Quest Diagnostics will validate and offer a lab-developed test in the United States based on Augurex's 14-3-3η biomarker, which helps detect elevated levels of the 14-3-3η protein-associated with rheumatoid arthritis and a higher risk of joint damage and disease severity.
In September 2023, Globus Medical Inc., a US-based medical device company, merged with NuVasive Inc. to offer surgeons and patients a comprehensive range of musculoskeletal procedural solutions and advanced technologies. This merger aims to improve the overall continuum of care, expand the companies' global operations, and significantly enhance their portfolios in arthritis and orthopedic treatments. NuVasive, a US-based company, specializes in developing medical devices and procedures focused on orthopedic and idiopathic conditions.
Major players in the juvenile idiopathic arthritis diagnostic market are Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Agilent Technologies, Sartorius AG, Sysmex Corporation, Bio-Rad Laboratories, Beckman Coulter Life Sciences, DiaSorin, Miltenyi Biotec, Cytek Biosciences, BD Biosciences, Angstrom Biotech, Sony Biotechnology, Theradiag, J. Mitra, Chimera Biotech, Stratedigm, Apogee Flow Systems, and Avecon Healthcare.
North America was the largest region in the juvenile idiopathic arthritis diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in juvenile idiopathic arthritis diagnostic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the juvenile idiopathic arthritis diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The juvenile idiopathic arthritis diagnostic market consists of revenues earned by entities by providing services such as clinical evaluations, blood tests, ophthalmologic screenings, bone density scans, and synovial fluid analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The juvenile idiopathic arthritis diagnostic market also includes sales of bone density scanners, AI-based diagnostic software, imaging equipment, and biomarker-based diagnostic panels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Juvenile Idiopathic Arthritis Diagnostic Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on juvenile idiopathic arthritis diagnostic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for juvenile idiopathic arthritis diagnostic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The juvenile idiopathic arthritis diagnostic market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.